09/28/21 7:01 AMNasdaq : SLRX Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of TexasSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced the receipt of a $2.7RHEA-AIvery positive
09/27/21 8:03 AMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap ConferenceSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, ChiefRHEA-AIneutral
09/22/21 7:33 AMNasdaq : SLRX partnershipSalarius Pharmaceuticals and Fox Chase Cancer Center Launch Research PartnershipSalarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced a research partnershipRHEA-AIneutral
09/20/21 7:33 AMNasdaq : SLRX Salarius Pharmaceuticals Added to FTSE Global Micro Cap IndexSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced its inclusion in the FTSERHEA-AIneutral
09/15/21 8:03 AMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Present at the Virtual Life Science Investor ForumSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, ChiefRHEA-AIneutral
09/08/21 8:13 AMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment ConferenceSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, ChiefRHEA-AIneutral
08/12/21 2:00 PMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth InvitationalSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, ChiefRHEA-AIneutral
08/05/21 7:32 AMNasdaq : SLRX earningsSalarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company ProgressClinical Trial in Hematologic Cancers Initiated and Initial Patients Enrolled in Expanded Sarcoma Clinical Trial; Multiple Potential Data Readouts Expected in 2021 and 2022 Preliminary Efficacy Findings from Sarcoma and Advanced Solid Tumor Trials Presented at American Society of Clinical OncologyRHEA-AIneutral
07/29/21 7:33 AMNasdaq : SLRX conferencesearningsSalarius Pharmaceuticals to Report Second Quarter 2021 Financial ResultsSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,RHEA-AIneutral
07/14/21 8:05 AMNasdaq : SLRX conferencesSalarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets SummitSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solidRHEA-AIneutral